Alpha Cognition (ACOGF) Stock Price, News & Analysis

Company Overview

Alpha Cognition Inc., a clinical stage biopharmaceutical company, develops treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062 for the treatment of mild-to-moderate Alzheimer's disease and mild traumatic brain injury; ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.

Key Stats

• Today's Range: N/A
• 50-Day Range: C$0.35 to C$9.44
• 52-Week Range: N/A
• Volume: 179,500 shs
• Average Volume: 78,954 shs
• Market Capitalization: C$52.80 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ACOGF Stock Analysis - Frequently Asked Questions

How were Alpha Cognition's earnings last quarter?

Alpha Cognition Inc. (OTC:ACOGF) released its quarterly earnings results on Monday, August, 12th. The company reported ($0.01) EPS for the quarter, beating analysts' consensus estimates of ($0.04) by $0.03.

How do I buy shares of Alpha Cognition?

Shares of ACOGF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

• Last Earnings: 8/12/2024
• Today: 12/26/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: OTC
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: N/A
• Current Symbol: OTC:ACOGF
• CUSIP: N/A
• CIK: N/A
• Web: www.alphacognition.com
• Phone: 604-564-9244
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): C($0.12)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: C$-13,770,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -522.43%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.96
• Quick Ratio: 0.96

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: C($0.04) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 150,856,000
• Free Float: 103,306,000
• Market Cap: C$52.80 million
• Optionable: Not Optionable
• Beta: 2.80